AKT1 and neoplasm: As expected, BYL-719 or LY290042 treatment reversed the tumorigenic effects of TSP50 and the TSP50-induced promotion of AKT phosphorylation in tumor tissues (Fig. 11A-F, Fig. S13A-F).